BNGO
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano\'s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns.
Bionano Genomics, Inc. (BNGO) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B- (3.0) | B- (3.0) | B- (3.1) | C+ (2.7) | C+ (2.6) | B- (2.9) |
| 2026-11-10 | B- (3.0) | B- (3.1) | C+ (2.6) | B (3.2) | C+ (2.6) | B- (2.9) |
| 2026-11-03 | B- (3.0) | B- (3.1) | C+ (2.6) | B (3.3) | C+ (2.7) | B- (2.9) |
| 2026-10-27 | B- (3.0) | B- (3.1) | C+ (2.6) | B (3.3) | C+ (2.6) | B- (2.9) |
| 2026-10-20 | B- (3.0) | B- (3.1) | C+ (2.6) | B (3.3) | C+ (2.6) | B- (2.9) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe